Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has granted an approval to Spectrum Pharmaceuticals regarding not to use bioscan - Indium-111 Zevalin imaging dose followed by a gamma scan - before administering the Zevalin therapeutic dose.
Subscribe to our email newsletter
Spectrum said with the approval of removing bioscan, patients undergoing treatment with Zevalin will now receive two infusions of rituximab, followed by a 10-minute injection of Zevalin (RRZ).
Zevalin (ibritumomab tiuxetan) intravenous injection is used to treat patients with previously untreated follicular non-Hodgkin Lymphoma (NHL).
Spectrum Pharmaceuticals MD chairman, CEO and president Rajesh Shrotriya said with this approval, they believe that physicians, patients and payers will find Zevalin to be an exceedingly more attractive treatment option.